BioStock: Prolight's CTO focuses on CRO partner MDx
Prolight Diagnostics is currently preparing for the clinical study to launch its high-sensitivity point-of-care troponin assay. To conduct the study, the company has chosen the clinical research organisation MDx. BioStock spoke to CTO Steve Ross about the importance of selecting a good CRO to ensure that the study is delivered successfully.
Read the full article at biostock.se:
https://biostock.se/en/2025/12/prolights-cto-satter-fokus-pa-cro-partnern-mdx/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se